NEW BRUNSWICK, N.J. — Johnson & Johnson has completed its acquisition of Halda Therapeutics, adding a clinical-stage biotechnology company and its proprietary oral cancer therapy platform to the company’s oncology portfolio in a transaction valued at $3.05 billion in cash.
Company officials said the acquisition strengthens Johnson & Johnson’s long-standing focus on prostate cancer by bringing in Halda’s lead clinical-stage asset, HLD-0915, a once-daily oral therapy designed to target and eradicate cancer cells while overcoming key resistance pathways. The therapy is based on Halda’s Regulated Induced Proximity Targeting Chimera, or RIPTAC, platform, which is intended to enable highly targeted treatments for solid tumors.
“This strategic milestone underscores our commitment to redefining cancer treatment with breakthrough science and transformative medicines,” said Jennifer Taubert, executive vice president and worldwide chairman of Innovative Medicine at Johnson & Johnson. “We are excited to formally welcome the talented Halda team and look forward to working together to achieve our shared goal of eliminating cancer.”
In addition to HLD-0915, the acquisition includes several earlier-stage oncology candidates targeting breast, lung, and other tumor types. Johnson & Johnson said the RIPTAC platform could also support the development of future targeted therapies beyond oncology.
“Johnson & Johnson continuously seeks new ways to meet patient needs and deliver innovative therapies,” said John C. Reed, M.D., Ph.D., executive vice president of Innovative Medicine research and development. “With the acquisition finalized, we will focus on advancing this promising pipeline and leveraging the RIPTAC platform to discover additional molecules in oncology and other disease areas.”
The company said the transaction will be accounted for as a business combination. With the deal closing in 2025, Johnson & Johnson expects earnings dilution in the fourth quarter of 2025 and in 2026. Total dilution to adjusted earnings per share is expected to be approximately $0.20, split evenly between the two years, reflecting non-recurring charges related to employee equity awards, financing, and integration costs. The company said it will provide additional guidance for 2026 during its fourth-quarter earnings call scheduled for January 21, 2026.
